Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novel acetyl-CoA carboxylase 2 inhibitors prepared at Boehringer Ingelheim

April 3, 2012

Studies further delineate clinical efficacy of mipomersen

April 3, 2012

Trials reveal efficacy of REGN-727 in treating hypercholesterolemia

April 3, 2012

Roche divulges novel HDL cholesterol-increasing agents

April 2, 2012

Immunotherapy potently reduces LDL cholesterol in phase I trials

April 2, 2012

Novel acetyl-CoA carboxylase 2 inhibitors presented

April 2, 2012

Pfizer and Astellas amend Lipitor licensing agreement

March 30, 2012

Zeria files for approval of oral phosphate hypophosphatemia drug in Japan

March 30, 2012

Antisense therapy shows promise in phase I study

March 30, 2012

Anacetrapib improves dyslipidemia in Japanese trial

March 30, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...